Business
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of
About this update from Caredx, Inc.
[{"type":"text","content":" BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the United States District Court for the District of Delaware (the “District Court”) issued an injunction prohibiting Natera (Nasdaq: NTRA) from continuing to falsely advertise and overstate the scientific performance of its Prospera transplant test. A copy of the injunction is available here.\n\n\nThe injunction follows the July 17, 2023, decision by the District Court to uphold and reaffirm the March 2022 jury verdict finding that Natera (Nasdaq: NTRA) violated the Lanham Act by falsely advertising the scientific performance of its Prospera transplant test. At the conclusion of the March 2022 trial, the jury found that Natera intentionally and recklessly misled the transplant community by deliberately engaging in false advertising in the promotion and marketing of its Prospera kidney transplant rejection assessment test. Overwhelming evidence emerged at trial that demonstrated that Natera made false statements to market Prospera that its senior executives knew were based on unscientific, unreliable, and inappropriate conclusions.\n\n\nOn July 17, 2023, the District Court upheld the jury’s prior decision that Natera made nine false advertising claims about its Prospera kidney transplant test and false advertising comparisons to CareDx’s AlloSure® Kidney to the transplant community. CareDx notes that the Company intends to appeal the District Court’s decision regarding the monetary damages awarded by the jury.\n\n\nThis injunction is a win for the transplant community because patient care and science won over false advertising.\n\n\nAbout CareDx – The Transplant Company\n\n\nCareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more informa...